DBCO-(PEG)3-VC-PAB-MMAE is a drug-linker conjugate for ADC, formed by connecting Monomethylauristatin E (MMAE) to a DBCO-(PEG)3-vc-PAB linker. DBCO-(PEG)3-VC-PAB-MMAE can be used for research related to cancer[1].
References:
[1] Karsten L, Janson N, Le Joncour V, et al. Bivalent EGFR-Targeting DARPin-MMAE Conjugates. Int J Mol Sci. 2022 Feb 23;23(5):2468.
DBCO-(PEG)3-VC-PAB-MMAE是由Monomethylauristatin E(MMAE)连接到DBCO-(PEG)3-vc-PAB接头上的活性分子偶联物(drug-linker conjugate for ADC)。DBCO-(PEG)3-VC-PAB-MMAE可用于癌症的相关研究[1]。
















